2,959 results on '"Lenz, Heinz‐Josef"'
Search Results
152. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
153. Disparities among Black and Hispanic colorectal cancer patients: Findings from the California Cancer Registry
154. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer
155. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study
156. Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study
157. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
158. Biomarker-driven and molecular targeted therapies for colorectal cancers
159. Outlooks on Epstein-Barr virus associated gastric cancer
160. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
161. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
162. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
163. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
164. Listening in on difficult conversations: an observational, multi-center investigation of real-time conversations in medical oncology
165. Reply to A. Sartore-Bianchi et al.
166. Quantitative evidence for early metastatic seeding in colorectal cancer
167. Safety and Tolerability of c-MET Inhibitors in Cancer
168. VEGF Ligands
169. Integration of Patient-Derived Organoids and Organ-on-Chip Systems: Investigating Colorectal Cancer Invasion within the Mechanical and GABAergic Tumor Microenvironment
170. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162–170
171. Sexual dysfunction among early-onset colorectal cancer survivors: Sex-specific correlates of sexual health discussions between patients and providers
172. Colorectal cancer: epigenetic alterations and their clinical implications
173. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer
174. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
175. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
176. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
177. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
178. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer
179. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer
180. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
181. How I Treat Early-Stage Colon Cancer With Adjuvant Therapy: Who and How Long?
182. Overview of Oncology Biomarkers
183. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
184. First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
185. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma
186. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
187. Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes
188. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor–Induced Thyroiditis
189. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
190. Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population
191. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer
192. Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer
193. Publisher Correction: Shared heritability and functional enrichment across six solid cancers
194. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims
195. Patient Care Satisfaction and Emergency Room Utilization among Young Adult Colorectal Cancer Survivors during the SARS-CoV-2 Pandemic: Lessons Learned
196. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
197. Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes
198. Author Correction : Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
199. Real-world (RW) testing patterns of serum lactate dehydrogenase (LDH) and its prognostic value among patients (pts) with metastatic colorectal cancer (mCRC).
200. Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.